Charles Gross

-Reuters

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S.

-Reuters

On February 24, 2023, Sunshine Biopharma, Inc. (the "Company") entered into an Exclusive Patent License Agreement (the "License Agreement") with Arizona Board ofRegents on behalf of the University of Arizona (the "University").

https://www.ft.com/content/b41bdc29-3a1f-4ff6-9872-f0625c505b46

NFIB Small Business Optimism for Jan 90.3 Vs Consensus 90.9 ... - Benzinga

Market On Close Imbalance: $1B To BUY-Side - SPDR S&P 500 ... - Benzinga

Bed Bath & Beyond Option Alert: Mar 3 $3 Calls Sweep (6) near the ... - Benzinga

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216338

-Wall Street Journal

Eurozone PPI YoY For Dec +24.6% Vs +22.6% Consensus; +1.1 ... - Benzinga

-South China Morning Post https://www.scmp.com/economy/global-economy/article/3208611/taiwans-export-orders-down-23-cent-china-and-hong-kong-lead-decline-despite-reopening?module=live&pgtype=homepage

-Reuters https://www.reuters.com/markets/deals/chinas-ev-giant-byd-talks-acquire-insurer-yian-2023-01-31/#:~:text=SHANGHAI%2C%20Jan%2031%20(Reuters),a%20crackdown%20on%20financial%20conglomerates.

-The Streamable https://thestreamable.com/news/fubotv-will-lose-some-cbs-affiliates-monday-how-to-keep-watching

Top Wall Street Bets Mentions For Friday January 27, 2023: TSLA ... - Benzinga

-Reuters

RLX Technology Option Alert: Mar 17 $3 Calls Sweep (55) near the ... - Benzinga

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

-Wall Street Journal Citing Government Spokesman